Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > From reuters

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on May 16, 2022 4:05pm

129 Views

Post# 34687294

RE:From reuters

We're in the hot pipeline asset, now let's just get that darn efficacy. I recall that management has always been consistent in talking about the platform - SORT1+ --as something that will (if it works) make existing drugs much more effective and enhance overall performance of many drugs.

This article also makes it seem like Novartis is the big pharma that needs some help in the area.

qwerty22 wrote: This couldn't be more bullish about targeted cancer therapy. When it comes to general discussions like this there's no difference between ADCs and PDCs, the potential is the same.

https://www.reuters.com/breakingviews/super-chemo-will-be-big-pharmas-next-tussle-2022-05-16/

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing